Andy Udell

CCO at Actinigen Medical

Speaker

Andrew Udell is a seasoned biotech and pharmaceutical executive with a track record of building and scaling organizations, launching innovative therapies, and driving significant revenue growth. With deep expertise in rare diseases, CNS, and specialty pharmaceuticals, he has played a pivotal role in high-profile acquisitions exceeding $1 billion.

As President of North America for Calliditas Therapeutics, Andrew led the successful U.S. launch of TARPEYO, generating over $100M in net sales and contributing to the company’s $1.1B acquisition. Previously, at NeuroDerm and Clinical Data Inc., he was instrumental in strategic commercial planning, leading to $1.1B and $1.2B acquisitions, respectively.

Currently, Andrew serves as Chief Commercial Officer at Actinogen Medical and leads his own consulting firm, advising biotech and pharmaceutical companies on commercialization, corporate strategy, and business development. An accomplished speaker and industry leader, he is recognized for his expertise in helping clinical-stage biotech companies transition to market-ready and commercial organizations.